Harmony Biosciences Collaborates with Bioprojet to Develop TPM-1116 as a Treatment of Narcolepsy and Other Sleep/Wake Disorders
Shots:
- Harmony Biosciences has entered into an exclusive licensing agreement with Bioprojet for the development, manufacturing & commercialization of TPM-1116 across the US & Latin American territories as a treatment for narcolepsy & other sleep/wake disorders
- Under the collaboration, Bioprojet will receive a $25.5M upfront license fee for exclusively developing, manufacturing & commercializing TPM-1116, ~$127.5M development & regulatory milestones, ~$240M sales-based milestones plus mid-teens sales-based royalties
- TPM-1116 is a potent & selective oral orexin-2 receptor (OX2R) agonist that demonstrated a robust safety profile and a potential for QD dosing in its preclinical study
Ref: Harmony Biosciences | Image: Harmony Biosciences
Related News:- Harmony Biosciences to Acquire Zynerba for ~$200M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
